Lv1
76 积分 2024-02-23 加入
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
2个月前
已完结
TET methylcytosine dioxygenases in cancer: Orchestrators of pathogenesis, immunity, immunotherapy, and chemoresistance
2个月前
已完结
Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation
2个月前
已完结
Dysregulation of DNA methylation in colorectal cancer: biomarker, immune regulation, and therapeutic potential
2个月前
已完结
Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers
3个月前
已完结
Epigenetic Modifications as Therapeutic Targets
3个月前
已完结
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
3个月前
已完结
Cell cycle dysregulation in cancer
4个月前
已完结
Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance
5个月前
已完结
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
5个月前
已完结
皖公网安备34019202002308
